Monitoring CMV immunity in lung transplant patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and feasibility of a laboratory test that measures the immune response to cytomegalovirus (CMV) in lung transplant recipients. By using the inSIGHT™ CMV T Cell Immunity Panel, the study seeks to determine how long patients can safely take the antiviral medication valganciclovir after their transplant. The goal is to tailor the duration of antiviral prophylaxis based on individual immune responses, potentially reducing unnecessary medication exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Received a lung transplant, or multi-organ transplant involving a lung at NYU Langone Health
2. Pre-existing serological immunity to CMV (R+)
3. Able and willing to provide informed consent

Exclusion Criteria:

1. Anti-thymocyte globulin induction immunosuppression
2. Perioperative desensitization
3. Pregnant or breastfeeding women

Where it's running

• NYU Langone Health
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Luis Angel, MD — NYU Langone Health
• Study coordinator: Tyler Lewis
• Email: Tyler.lewis@nyulangone.org
• Phone: 866-838-5864

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Research on improving outcomes for lung transplant donors and recipients

  This study is trying to see how different donor and medical practices affect the health of lung transplant patients and donors, while also looking for blood markers that might predict complications after the surgery.

  Recruiting at 19 sites Duke University · Los Angeles, California and 18 other locations · NCT06399302

• Multidisciplinary non-drug program to improve quality of life after solid organ transplant

  A multidisciplinary, non-drug program using acupuncture, remote physical rehab, and brain-health activities is being tested to see if it can improve quality of life for adults at least one year after heart, kidney, liver, or lung transplant.

  Recruiting The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · Palermo, Palermo · NCT07870811

• Multimodal prospective approach to understand acute and chronic lung transplant rejection

  This project will see if blood tests, airway sampling, imaging, and genetic analyses can identify which adults who have had or are being evaluated for a lung transplant will develop antibody‑mediated rejection and later chronic graft dysfunction.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07516379

• Airway response to exercise after double lung transplant

  This study will see if short (5-minute) versus longer (15-minute) constant-work exercise causes different airway narrowing and breathlessness in people who have had a double lung transplant.

  Recruiting Chang Gung Memorial Hospital · Taoyuan · NCT07035743

• Measuring breathing effort before and after removing the breathing tube

  This will test a new electrical impedance method to measure breathing effort in adults on ventilators as they try breathing on their own and after the breathing tube is removed.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07017608

• Cryo nerve block to improve recovery after bilateral lung transplant

  This pilot will test whether adding a cryo nerve block around the chest helps people with end-stage COPD recover better after a bilateral lung transplant.

  Recruiting University Hospital, Gasthuisberg · Leuven, Vlaams-Brabant · NCT06959056

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.